Myeloma cells inhibit osteogenic differentiation of mesenchymal stem cells and kill osteoblasts via TRAIL-induced apoptosis by Fu, Jinxiang et al.
Myeloma cells inhibit osteogenic differentiation 
of mesenchymal stem cells and kill osteoblasts via 
TRAIL-induced apoptosis
Jinxiang Fu
1, Panjun Wang
1, Xiaohui Zhang
1, Suguang Ju
2, Jie Li
3, Binzhou Li
1, Sun Yu
1, Jianhua Zhang
1,
Xueguang Zhang
2
Abstract
Introduction: Myeloma bone disease (MBD) is the result of the increased activity
of osteoclasts (OCs), which is not accompanied by a comparable increase of
osteoblast (OB) function, thus leading to enhanced bone resorption. Osteoblasts
can also regulate osteoclast activity through expression of cytokines, such as
receptor activator of nuclear factor-κB ligand (RANKL), which activates osteoclast
differentiation, and osteoprotegerin (OPG), which inhibits RANKL by acting as
a decoy receptor.
Material and methods: Based on a series of 21 patients with multiple myeloma
(MM) and human osteoblast cell line HFOB1.19, we provide evidence that the
bone marrow-derived mesenchymal stem cells (BMMSCs) of patients with MM
exhibit normal phenotype, but showed reduced efficiency to differentiate into
OBs as compared with normal controls. 
Results: In vitro assays showed that MM cells inhibited the potential of osteogenic
differentiation of BMMSCs from healthy controls and rendered the OBs sensitive
to TRAIL-induced apoptosis. There was no evidence of the formation of tartrate-
resistant acid phosphatase positive OCs. The osteogenic differentiation of
HFOB1.19 was also inhibited in the presence of RPMI 8266 or XG7 MM cells, as
confirmed by von Kossa and ALP staining. Osteoblast s induced from BMMSCs
supported survival and proliferation of MM cells, especially when the MM cells
were cultured in medium containing rhTRAIL and dexamethasone. Multiple
myeloma cells proliferated and grew well in the presence of residual OBs.
Conclusions: Besides OCs, our results demonstrated that OBs and MM cells were
dependent upon each other and made a microenvironment suitable for MM
cells.
Key words: multiple myeloma, osteoblast, recombinant human tumour necrosis
factor (TNF)-related apoptosis-inducing ligand (TRAIL), myeloma bone disease
(MBD).
Introduction
Multiple myeloma (MM) is the most common form of plasma cell
dyscrasia, affecting B cells that have traversed the post-germinal centre.
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Plasma cells in MM first enter blood vessels in the
peripheral blood, from where they eventually
migrate to, survive in and expand exclusively in the
bone marrow. At advanced stages, myeloma cells
can grow independently of the bone marrow
microenvironment, causing a more aggressive
presentation of the disease, which includes mainly
lytic lesions, pathological fractures, hypercalcaemia
and osteoporosis [1-3]. Myeloma bone disease
(MBD) is the result of the increased activity of
osteoclasts, which is not accompanied by
a comparable increase of osteoblast function, thus
leading to enhanced bone resorption [4, 5].
Osteolytic lesions in multiple myeloma are only
found adjacent to intramedullary plasma cell foci
or plasmacytomas, suggesting that MM cells may
secrete factors that promote activation of
osteoclasts, and inactivation of osteoblast function
to replace the bone loss. This peculiar feature of
MBD is sustained by the extreme paucity of
osteocytes or newly formed bone within the erosion
sites. Enhanced bone resorption, however, is not
accompanied by concurrent enhancement even in
patients achieving chemotherapy-induced complete
remission [6]. Osteoblasts originate mainly from
mesenchymal stem cells (MSCs) and are responsible
for bone matrix synthesis by secreting collagen,
which form strands called osteoids [7]. Osteoblasts
can also regulate osteoclast activity through
expression of cytokines, such as RANKL, which
activates osteoclast differentiation, and
osteoprotegerin (OPG), which inhibits RANKL by
acting as a decoy receptor [8]. Investigation of the
reduction of osteoblast activity in MM has been
overshadowed by the volume of work focused on
the role of hyperactivated osteoclasts [9]. 
Tumour necrosis factor (TNF)-related apoptosis-
inducing ligand (TRAIL), first discovered in 1995, is
a member of the TNF superfamily that induces
apoptosis through engagement of death receptors.
TRAIL induces apoptosis in numerous types of human
tumours and rodent xenograft models [10],
including MM [11-13], while exerting minimal or no
toxicity in normal cells. TRAIL interacts with a complex
system of receptors in human cells: 2 proapoptotic
death receptors (DR4 and DR5), which have
cytoplasmic death domains, and 2 decoy receptors,
which are functionally inactive (DcR1 and DcR2). 
Besides tumour control by TRAIL+ immune cells,
there is accumulating evidence that death receptor
ligands might also be used by tumour cells
themselves to kill bystander cells in a mechanism
called “tumour counterattack” [14-16]. The
mechanisms involved in the pathogenesis of MBD
are not fully elucidated, though the prevalent
opinion is that malignant plasma cells exert a major
osteoclastogenic effect by promoting the
recruitment, differentiation and activation of
osteoclast progenitor within the bone marrow
following their interaction with the MSCs. In the
present study, we tried to elucidate whether the
formation of bone lesions that develop with high
frequency in MM patients is mediated, at least in
part, by interaction of myeloma cells and
osteoblasts either through TRAIL or by inhibiting
osteoblastic potential of mesenchymal stem cells,
thereby inducing cell death in the bone cell fraction.
Moreover, effects of osteoblasts on proliferation and
survival of MM cells, especially in medium
containing dexamethasone or with TRAIL, were also
investigated using a co-culture technique in vitro. 
Material and methods
Culture of mesenchymal stem cells derived
from bone marrow
Twenty-one patients with newly diagnosed MM,
whose median age was 56 years (range 31-74
years), were studied before any treatment with
informed consent. Among these patients, 3 were
in stage I or II of the disease and the rest were in
stage III. Mononuclear cells (MNCs) were separated
from bone marrow of patients mentioned above
and normal controls by Ficoll-Hypaque density
gradient centrifugation. To remove haematopoietic
stem cells and prevent overgrowth of the cultures
with macrophages, CD45+ cells were depleted by
negative immunomagnetic cell selection using the
Mini MACs device (Miltenyi Biotec, Germany)
according to the manufacturer’s instructions.
Samples obtained before and after depletion of the
CD45+ cells were analysed by flow cytometry (FCM).
The resulting CD45-depleted MNCs were cultured
as described previously [17]. When adherent cells
(primary culture, P0) reached 80% confluence, cells
were isolated by treatment with 0.25% trypsin
(Invitrogen, USA)/EDTA (Sigma, USA) and cultured
immediately at 103 cells/cm2 under the same
conditions (first passage, P1). BMMSCs at P0 and
P1 were used immediately or frozen until use.
Culture of human osteoblast cell line HFOB1.19
The human osteoblast cell line HFOB1.19 was
bought from Shanghai Cell Bank, Academy of Cell
Science, China. According to their instructions, the
cells were cultured at 2 × 105/ml in α-MEM + 10%
fetal calf serum (FCS). Then the cells were fed twice
a week until confluence. HFOB1.19 cells were
detached using 0.25% trypsin and counted using
trypan blue exclusion. HFOB1.19 cells were used
after expansion in vitro or frozen until use.
Flow cytometry analysis
The phenotypes of both BMMSCs and HFOB1.19
were determined by flow cytometry (FCM) with
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FITC- or phycoerythrin-conjugated anti-CD90,
CD106, CD44, CD45, CD13, CD14, CD73, anti-human
TRAIL-R1, TRAIL-R2 and anti-human TRAIL monoclonal
antibodies (all from Invitrogen, USA). Expression of
TRAIL of MM cell lines RPMI 8266 (ATCC, USA) and
XG7 (gratefully donated by Prof. Zhang Xueguang,
Institute of Biotechnology, Soochow University) was
also analysed with FCM. Samples were analysed on
an EPICS-ALTRA flow cytometer (Beckman Coulter,
USA) using EXPO2 software. Expression level of
each molecule was quantified as the mean
fluorescence intensity (MFI).
Differentiation of bone marrow-derived
mesenchymal stem cells into osteoblasts
Bone marrow-derived mesenchymal stem cells
(P0 or P1) and HFOB1.19 were seeded alone at
104/cm2 in 6-well culture plates in DMEM with 
4.5 g/l glucose supplemented with 10% FCS, 0.1 µM
dexamethasone and 50 µg/ml ascorbic acid (Sigma,
USA). The MM cell line RPMI 8266 or XG7 pre-
cultured in the same culture medium was added to
the cultures above at a dose of 105 cell/ml at the
beginning of culture and at day 7. Culture medium
was changed twice a week. After 3 weeks’
incubation, the culture was washed with
phosphate-buffered saline (PBS) and stained for
alkaline phosphatase (ALP) and von Kossa using
a commercial assay kit (Protein Assay, USA). To
exclude the possible effects of osteoclasts in a co-
culture manner, tartrate-resistant acid phosphatase
(TRAP, Sigma, USA) staining was used at the same
time. 
Role of TRAIL on proliferation of HFOB1.19 and
bone marrow-derived mesenchymal stem cells
in vitro
To determine whether TRAIL has a proliferative
or apoptotic effect on osteoblasts, the HFOB1.19
cells were cultured at a density of 2 × 103/ml in 
96 and 6-well plates in α-MEM + 10% FCS with 
25 ng/ml, 50 ng/ml, 100 ng/ml and 200 ng/ml
rhTRAIL (Invitrogen, USA). After incubation for 
24 h, cell viability was determined with the MTT
assay and was expressed as percentage of the
corresponding values for control cells. The
percentages of apoptotic HFOB1.19 cells were
determined with the annexin V/PI assay. The role
of TRAIL on osteoblasts induced from BMMSCs was
also investigated with the same method with TRAIL
at a concentration of 50 ng/ml.
Multiple myeloma cells and osteoblast 
co-cultures
For determination of cytotoxic activity of
myeloma cells on osteoblasts, we performed direct
and indirect co-culture experiments. 
1) Direct contacted groups: (1) RPMI 8266 or XG7
was cultured in 1 ml of α-MEM with 50 ng/ml
rhTRAIL without osteoblasts; (2) the osteoblasts
or HFOB1.19 were cultured with XG7 or PRMI
8266 MM cells in 1 ml of α-MEM with 50 ng/ml
rhTRAIL; (3) the osteoblasts and HFOB1.19, which
were pre-incubated with XG7 or PRMI 8266 MM
cells for 24 h, were cultured in medium
containing 50 ng/ml rhTRAIL; (4) the osteoblasts
and HFOB1.19 were cultured with XG7 or PRMI
8266 MM cells without rhTRAIL; (5) the
osteoblasts and HFOB1.19 were cultured with XG7
or PRMI 8266 MM cells with 10 µg/ml anti-TRAIL-
R1/R2 mab. 
2) Indirect contacted groups: Transwell (0.45-µm
pore size, Corning Co, USA) culture system was
used in this group according to the
manufacturer’s instructions. (1) The osteoblasts
and HFOB1.19 in the lower chamber and
RPMI8266(XG7) in the upper chamber with
50 ng/ml rhTRAIL; (2) the osteoblasts and
HFOB1.19 in the lower chamber and
RPMI8266(XG7) in the upper chamber without
rhTRAIL; (3) the osteoblasts and HFOB1.19 in the
lower chamber and RPMI8266(XG7) in the upper
chamber with 10 µg/ml anti-TRAIL-R1/R2 mab.
The percentages of apoptotic BMMSCs,
HFOB1.19, and MM cells were determined by the
annexin V/PI assay. 
Effects of osteoblasts on multiple myeloma cells
Bone marrow-derived mesenchymal stem cells
and HFOB1.19 were seeded alone at 104/cm2 in 
24-well culture plates in osteoblastic-inducing
medium as mentioned above for 14 days. The pre-
culture cells were washed 3 times with PBS to
detach and remove the non-adherent cells.
RPMI8266 and XG7 MM cells (5 × 105 cells/ml in 
α-MEM medium) were cultured alone or added to
resulting osteoblasts in vitro. Culture medium was
changed twice a week. At the end of day 3, 7, 10
and 14, MM cells were counted. To test the effects
of OBs on survival of MM cells, RPMI8266 and
XG7 MM cells were plated to 6-well plates at
a concentration of 5 × 105/well alone or containing
freshly prepared OBs in medium with 2 × 10–7 M
dexamethasone or 50 ng/ml rhTRAIL. The cultures
were continued for 48 h and cell numbers, viability
(trypan blue assay) and annexin V/PI binding were
determined by flow cytometry.
Data procedure
Unless otherwise indicated, all values are
expressed as mean ± SE. Statistical analysis was
performed using SPSS software (Chicago, IL).
Statistical significance was determined using the
nonparametric Mann-Whitney U test or Student’s
t test. A value of p < 0.05 was considered significant.
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Results
Morphological characteristics of in vitro-
cultured bone marrow-derived mesenchymal
stem cells and flow cytometric data
Human BMMSCs were cultured as described in
the Material and methods section. As early as 2 h
post-incubation, CD45-depleted MNCs began to
adhere to the wells and attachment increased with
time. The round and stellate cells began to form small
colonies after approximately 5 days in culture and
CFU-F were fully established by day 7-10 (Figure 1).
Confluent BMMSC cultures were obtained from 
20 out of 21 patients and all controls after 14 and 13.5
days, respectively. There was no difference between
the cells from MM and normal controls with respect
to their morphological characteristics, number of
generated BMMSCs per cm2 and patient age. In the
cases, BMMSC phenotypes were analysed at passage
2. The BMMSCs from patients or normal controls
displayed similar antigen expression (p> 0.05 for each
antigen tested) with no expression of haematopoietic
lineage antigens such as CD34, CD45 and CD14 and
high expression of CD44, CD106, CD73, CD90 and
Figure 1. Morphological characterization of BMMNCs.  A – BMMNCs cultured for 5 days, B – BMMNCs at day 12 (100×)
AB
Figure 2. von Kossa staining mineralized crystal generated from BMMSCs. A and a – from normal controls and MM
patients respectively after 21 days incubation with osteogenic inducing medium (100×). B and b – from normal
controls and MM patients respectively after incubation with osteogenic condition medium and RPMI 8266
A a
Bb
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CD13, while it is confirmed by FCM that HFOB1.19 only
expressed CD44 and CD90 out of the above antigens. 
The studies also demonstrated that HFOB1.19
moderately expressed TRAIL-R2 and did not express
TRAIL-R1, but we failed to detect either TRAIL-R1 or
TRAIL-R2 expression on BMMSCs.
Multiple myeloma cells inhibit the osteogenic
differentiation of bone marrow-derived
mesenchymal stem cells in vitro
When cultured in monolayer osteogenic
conditions, the BMMSCs isolated from MM patients
and healthy controls acquired an osteoblastic
morphology demonstrated by deposition of a calcium-
rich mineralized extracellular matrix (Figure 2A).
Mineralized crystal appeared in BMMSC cytoplasm
after 2 weeks, and the amount and volume of crystal
increased in a time-dependent manner. These findings
suggested that osteo  genesis of BMMSCs from MM
patients were qualitatively conserved, but it seemed
that the osteogenic differentiation of BMMSCs
from MM patients was partially damaged as
compared with the controls (Figure 2A and 2a). There
were a few calcium-rich mineralized deposits and low
activity of ALP in HFOB1.19 cells when stained with
von Kossa and ALP, but accumulation of mineralized
deposits and upregulation of ALP activity were seen
when the cells were cultured in osteogenic conditions
for 7 days. We then tested whether RPMI 8266 and/or
XG7 MM cell lines can affect differentiation of
BMMSCs in vitro. The differentiation of BMMSCs or
HFOB1.19 into osteoblast was inhibited in the
presence of RPMI 8266 or XG7 whether the MM cells
were plated at the beginning of culture or at 7 days
(Figures 2, 3). The mineralized crystal deposits in the
Figure  3. The change of ALP and mineralized
deposition in HFOB1.19 before and after cells were
cultured in osteogenic condition medium and RPMI
8266. Before the HFOB1.19 cells were incubated in
osteogenic inducing medium with RPMI 8266,
mineralized deposition and ALP activity were seen
with von Kossa and ALP staining. A – von Kossa
staining, a – ALP staining (100×). When the HFOB1.19
cells were incubated in osteogenic inducing medium
with RPMI 8266 for 7 days, decreased of mineralized
deposition and downregulation of ALP activity were
seen as cells was stained with von Kossa and
staining (B – von Kossa staining, b – ALP staining
(100×), C – there was no TRAP positive found in co-
culture experiments
A a
Bb
C
Jinxiang Fu, Panjun Wang, Xiaohui Zhang, Suguang Ju, Jie Li, Binzhou Li, Sun Yu, Jianhua Zhang, Xueguang ZhangArch Med Sci 4, August / 2010 501
cells decreased significantly in comparison with
controls. There were no tartrate-resistant acid
phosphatase (TRAP) positive cells found in our study
(Figure 3C).
Effects of TRAIL on osteoblasts
After demonstrating with FCM that HFOB1.19
moderately expressed TRAIL-R2/DR5, we then
investigated whether recombinant human TRAIL
(rhTRAIL) would inhibit the growth of HFOB1.19
when the cells were cultured at different
concentrations of TRAIL. HFOB1.19 was resistant to
TRAIL-induced apoptosis when the cells were
incubated for 24 h in the presence of rhTRAIL in
vitro. Expression of TRAIL did not render HFOB1.19
sensitive to apoptosis as detected by FCM. Similar
results were observed among the osteoblasts
induced from BMMSCs (Figure 4).
Myeloma cells rendered osteoblasts sensitive
to TRAIL-induced apoptosis
Since we observed inhibited osteogenic
differentiation of BMMSCs in co-culture experi  -
ments with myeloma cells, we next addressed
whether rhTRAIL would further increase cell death
of osteoblasts when co-cultured with myeloma cells.
We determined the total fraction of apoptotic
osteoblasts using FCM. Osteoblasts or HFOB1.19
were resistant to TRAIL when cultured alone, while
in co-culture with RPMI-8226 or XG7 cells a higher
percentage of apoptotic osteoblasts was observed,
which additionally increased following treatment
with rhTRAIL. The pre-incubation of osteoblasts
with MM cells rendered the osteoblasts sensitive
to TRAIL-induced apoptosis, but the proportion of
apoptotic cells decreased significantly as compared
with co-culture. The fraction of apoptosis in
osteoblasts induced by myeloma cells was
significantly decreased when direct cell-cell contact
was prevented with the Transwell culture system,
suggesting that primarily membrane-bound factors
are involved in myeloma-mediated cytotoxicity. The
incubation of RPMI-8226 cells with anti-TRAIL-R1
mab was ineffective in blocking killing of
osteoblasts, while the addition of anti-TRAIL-R2 mab
significantly reduced the percentage of apoptotic
osteoblasts. Similar results were seen when XG7
cells were used as effector cells (Figure 4C). 
Osteoblasts promote multiple myeloma cells
to proliferate and survive TRAIL-induced
apoptosis
Pre-cultured OBs were incubated alone or
cultured with RPMI 8266 or XG7 MM cells for 48 h
in medium containing rhTRAIL or dexamethasone.
The total number of myeloma cells recovered from
cultures of myeloma cells alone was significantly
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Figure 4. The OBs induced from BMMSCs or human
osteoblast cell line HFOB1.19 grew well in medium
containing rhTRAIL and were not sensitive to 
rhTRAIL induced apoptosis in vitro as MTT assays or
flow cytometry using the annexin V/PI binding assay
(A and B). The percentage of apoptosis increased
significantly whether the OBs or HFOB1.19 were pre-
cultured or co-cultured with XG7/RPMI 8266 MM
cells, but the proportion of apoptosis decreased
significantly when anti-TRAIL-R2 mab were added to
the cultured (C)
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lower than that from co-cultures and their viability
was also significantly lower, while their apoptotic
rate was significantly higher than that of myeloma
cells cultured with OBs (Table I, Figure 5). Our data
also showed that OBs could promote MM cells to
survive and grow in the presence of rhTRAIL and
dexamethasone.
Discussion
Normal bone constantly undergoes remodelling,
which involves the resorption of bone by osteoclasts
and the deposition of new bone by osteoblasts at
sites of previous resorption. In myeloma, many
different components interact to increase the bone
resorption process. These include myeloma cells
themselves, bone marrow stromal cells, and
T cells present in the marrow microenvironment.
Furthermore, growth factors released by the bone
resorption process also increase the growth of
myeloma cells. This creates a vicious cycle and finally
induces increased bone resorption. This osteolytic
bone disease is responsible for the most debilitating
clinical symptoms of MM, which include bone pain,
pathological fractures, spinal cord compression,
hypercalcaemia, renal failure, and death [18-20].
Recently studies have been supported by clinical
evidence showing that MM patients with advanced
bone lesions may have a reduction of bone formation
markers, such as alkaline phosphatase and
osteocalcin, together with the increased bone
resorption [21, 22]. Similarly, marked osteoblastopenia
and reduced bone formation have also been reported
in murine models of MM that develop bone lesions
[23-25]. These data suggest that MM cells suppress
osteoblasts and thereby inhibit bone formation. Wnt
signalling pathway inhibitors DKK1 and sFRP-2 and
soluble cytokines IL-3 and IL-7 were all reported to
be inhibitors of bone formation in MM [26-28]. All of
these studies employed bone marrow stromal cells,
or pre-osteoblastic cell lines as the subjects. However,
there is no report on the potential and regulation of
osteogenesis of BMMSCs and interactions among
the MM cells, BMMSCs and osteoblasts. Bone
marrow-derived mesenchymal stem cells were the
main source of osteoblasts in bone marrow and
played a critical role in bone regeneration. We
hypothesize that the impaired osteogenesis of MM
patients may occur in stem cells more primitive than
stromal or pre-osteoblastic cells, such as MSCs, and
osteoblasts might promote MM cell survival or
growth in the special microenvironment of MM
patients.
A
B
C
Figure 5. RPMI 8266 and XG7 MM cells were sensitive
to TRAIL induced apoptosis (A), but the percentage of
apoptosis decreased when the cells were co-cultured
with osteoblasts (OBs); (B) MM cells and OBs were
incubated in medium containg 2 × 10–7 M dexa  -
methasone; (C) MM cells and OBs were incubated in
medium containing 50 ng/ml rhTRAIL
MM cells + rhTRAIL/Dex MM cells + OBs + rhTRAIL/Dex
Annexin V [%] Annexin V/PI [%] Alive [%] Annexin V [%] Annexin V/PI [%] Alive [%]
8226 18.08*/22.85* 54.07/62.84 27.66*/14.14* 4.21*/17.14* 35.74/44.01 57.71#/37.91*
XG7 35.49#/16.81* 36.76/41.36 26.24*/41.62* 4.32#/16.95* 14.76/32.71 80.92#/51.91*
*p < 0.05, #p < 0.01
Table I. Effects of OBs on MM cells in medium containing rhTRAIL and dexamethasone
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Arnulf  et al. [29], demonstrated that MSCs
isolated from MM expressed the typical expected
phenotype and had haematopoiesis-supporting
capacities similar to those of normal MSCs, but
these cells produced on average 2.5 times more IL-6
than MSCs from normal controls and were less
immunosuppressive than their normal counterparts.
In this study, we isolated and purified the MSCs
from BM of myeloma patients. Flow cytometry
analysis of BMMSCs from patients and healthy
controls displayed similar antigen expression with
no expression of haematopoietic lineage antigens
such as CD34, CD45 and CD14 and high expression
of CD44, CD106, CD73, CD90 and CD13. Von Kossa
staining showed that there were mineral deposits
in both BMMSCs, which suggested that
osteogenesis of BMMSCs from MM patients were
qualitatively conserved, but it seemed that 
the osteogenic differentiation of BMMSCs from
MM patients was partially impaired as compared
with the healthy controls. Importantly, these
characteristics were observed in the absence of MM
cells. We then tested whether RPMI 8266 and/or
XG7 MM cell lines can affect differentiation of
BMMSCs in direct contact manner in vitro. The
differentiation of BMMSCs into osteoblasts
decreased significantly in the presence of RPMI
8266 or XG7 whether the MM cells were plated at
the beginning of culture or at day 7. The
mineralized crystal deposition in the cells observed
was significantly less than that in controls. Lower
crystal deposition and low ALP activity in HFOB1.19
were observed when the cells were incubated in
the presence of MM cells. Evidence is provided to
support the existence of subsets of MM cells
expressed in the osteoclast phenotype, including
multinuclear morphology, cytoplasmic TRAP and
a specific osteoclast antigen [30], which may
contribute to MBD by producing osteoclast
enzymes. However, neither the phenotype nor the
functional properties of osteoclasts were detected
and no TRAP positive cells were found in our study.
These results suggest that the osteogenic potential
of MSCs of MM was decreased and they support
the notion that suppressed osteoblastic activity and
low bone formation contribute to the bone disease
found in MM patients.
It was reported recently that myeloma cell lines
sensitized osteoblasts to cell death mediated by
recombinant TRAIL, whereas primary osteoblasts
protected myeloma cells from TRAIL-mediated
apoptosis that was mediated by OPG [24]. Our
results demonstrate that expression of TRAIL-R2
did not render HFOB1.19 sensitive to apoptosis
induced by TRAIL as detected by FCM. Similar
results were observed among the osteoblasts
induced from BMMSCs. Neither OBs induced from
BMMSCs nor HFOB1.19 would sensitize to TRAIL-
induced apoptosis in vitro, but the proportion of
apoptosis increased whether the cells were
incubated with MM cells or pre-cultured with MM
cells. We observed significant killing of osteoblasts
in direct contact with MM cells and the fraction of
apoptosis in osteoblasts induced by myeloma cells
was significantly decreased when direct cell-cell
contact was prevented with the Transwell culture
system. The incubation of RPMI-8226/XG7 cells with
anti-TRAIL-R1 mab was ineffective in blocking killing
of osteoblasts, while the addition of anti-TRAIL-R2
mab significantly reduced the percentage of
apoptotic osteoblasts. Vice versa, RPMI-8226 or XG7
cells were sensitive to treatment with rhTRAIL. Their
sensitivity, however, decreased when they were
treated in co-culture with OBs. Interestingly, the
residual OBs had the ability to support survival
of MM cells in presence of dexamethasone or
rhTRAIL. The proportion of apoptotic MM cells
decreased significantly in comparison with controls.
Although myeloma cells did not firmly adhere 
to OBs, cell-cell contact was essential, as
demonstrated in non-contact experiments with OBs
or OB/MM cell co-cultures. This indicates that
soluble factors released by OBs alone or after their
direct interaction with MM cells are sufficient to
promote myeloma cell growth, which may be
parallel to the results of Shipman and Croucher [31].
In the meantime, it seemed that adhesive
interactions between myeloma and BMMSCs played
a significant role in the survival of MM cells and
might augment the bone-destructive process. Based
on these experiments, we hypothesized that
primarily membrane-bound factors are involved in
myeloma-mediated cytotoxicity and this process
might allow them to gain space within the bone
marrow necessary for their proliferation and
expansion. 
In conclusion, our BMMSC/myeloma cell co-
culture experiments clearly demonstrate that the
osteogenic differentiation of BMMSC from MM
patients was impaired, although the phenotype was
similar to the healthy controls. Multiple myeloma
cells inhibited the potential of osteogenic
differentiation of BMMSCs from healthy controls
and rendered the OBs sensitive to TRAIL-induced
apoptosis. Osteoblasts from healthy donors
supported survival and proliferation of MM cells,
especially when the MM cells were cultured in
medium containing rhTRAIL and dexamethasone.
This might explain in part the lower number of OBs
found from bone marrow of MM patients and
making a microenvironment suitable for MM cells.
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